Advertisement

Advertisement

Gynecologic Cancers
Immunotherapy

Avelumab for Patients With Gestational Trophoblastic Tumors Resistant to Single-Agent Chemotherapy

In the French phase II TROPHIMMUN trial reported in the Journal of Clinical Oncology, Benoit You, MD, PhD, and colleagues found that avelumab normalized human chorionic gonadotropin (hCG) levels in approximately half of women with gestational trophoblastic tumors resistant to single-agent...

Gynecologic Cancers

American Cancer Society Updates Guideline for Cervical Cancer Screening

An updated cervical cancer screening guideline from the American Cancer Society released today has called for less—and more simplified—screening. The guideline was published by Fontham et al in CA: A Cancer Journal for Clinicians. The updated guideline recommends that individuals with a cervix...

Gynecologic Cancers

Statin Use Linked to Improvement in Survival in Ovarian Cancer

Lipophilic statin use was associated with a reduced risk of dying of epithelial ovarian cancer in a large observational study. Compared with never users, women with epithelial ovarian cancer who were taking any type of statins had a reduced mortality of 40%, and those taking lipophilic statins had...

Gynecologic Cancers

LACC Trial: Quality-of-Life With Open vs Minimally Invasive Radical Hysterectomy for Patients With Cervical Cancer

As reported in The Lancet Oncology by Frumovitz et al, there were no significant differences in quality of life, a secondary endpoint, for women undergoing open vs minimally invasive radical hysterectomy for cervical cancer in the phase III LACC trial. There were, however, differences in...

Gynecologic Cancers

Quality of Life With Timing of Platinum-Based Regimens in Newly Diagnosed Patients With Ovarian Cancer

In a study reported in The Lancet Oncology, Blagden et al found lower mean global quality-of-life scores on longitudinal analysis among women with newly diagnosed ovarian cancer who received weekly vs every-3-week paclitaxel in platinum-based regimens in the ICON8 trial. The ICON8 trial showed no...

Gynecologic Cancers

Higher Risk of Disease Recurrence and Death With Minimally Invasive vs Open Surgery for Early-Stage Cervical Cancer

Women with early-stage cervical cancer treated with minimally invasive radical hysterectomy had a 71% increased risk of recurrence and a 56% increased risk of death compared with those treated with open radical hysterectomy, according to a systematic review and meta-analysis of 15 studies involving ...

Gynecologic Cancers
Immunotherapy

Addition of Trastuzumab to Carboplatin/Paclitaxel for Advanced or Recurrent HER2-Positive Uterine Serous Carcinoma

Combining the HER2-targeted therapy trastuzumab with carboplatin and paclitaxel improved survival rates for women with a rare, aggressive type of endometrial cancer, according to findings published by Fader et al in Clinical Cancer Research. Each year, more than 65,650 women in the United States...

Gynecologic Cancers

Expert Point of View: Robert L. Coleman, MD

Discussant of the DESKTOP III and SOC1 trials, Robert L. Coleman, MD, of U.S. Oncology Research in Woodlands, Texas, congratulated the authors of both trials. He put these results in perspective with the GOG-0213 study, which did not show a survival benefit for secondary surgery. “There are general ...

Gynecologic Cancers

Two Studies Report Secondary Surgery Extends Survival in Recurrent Ovarian Cancer

Two phase III trials provide support for secondary cytoreductive surgery in women with recurrent ovarian cancer, with the caveats that patient selection is key and the surgery should be performed at sites of excellence. The results of the DESKTOP III and SOC1 trials, both presented during the...

Gynecologic Cancers

Expert Point of View: Don S. Dizon, MD, FACP, FASCO

Commenting on the SOLO2 trial for The ASCO Post was Don S. Dizon, MD, FACP, FASCO, Director of Women’s Cancers at Lifespan Cancer Institute and Professor of Medicine at Brown University, Providence, Rhode Island. “It’s great to get an overall survival advantage from a PARP inhibitor study. Coming...

Gynecologic Cancers
Immunotherapy

Final Analysis of Phase II Trial in Recurrent Platinum-Sensitive Ovarian Cancer

In a poster presentation at the ASCO20 Virtual Scientific Program, Mansoor Raza Mirza, MD, of the the Department of Oncology, Rigshopitalet, Copenhagen University Hospital, Denmark, and colleagues reported the final analysis of the phase II NSGO-AVANOVA2/ENGOT-OV24 trial comparing the...

Gynecologic Cancers

Maintenance Olaparib Shows Overall Survival Benefit in Ovarian Cancer

In the final, preplanned, overall survival analysis in the randomized phase III SOLO2/ENGOT-ov211 trial, maintenance treatment with the PARP inhibitor olaparib extended overall survival by an unprecedented 12.9 months, compared with placebo. This marks the first time that overall survival has been...

Gynecologic Cancers
Immunotherapy

Expert Point of View: TROPHIMMUN Trial

Two gynecologic oncologists and ASCO’s Chief Medical Officer and Executive Vice President Richard L. Schilsky, MD, FACP, FSCT, FASCO, commented on the findings of the TROPHIMMUN trial for The ASCO Post. “The authors demonstrate efficacy of a new treatment approach for gestational trophoblastic...

Gynecologic Cancers
Immunotherapy

Avelumab Shown Effective in Rare Chemotherapy-Resistant Gynecologic Tumor in TROPHIMMUN Trial

Almost 50% of patients resistant to single-agent chemotherapy responded in the first trial of immunotherapy for gestational trophoblastic tumors, reported French investigators in an abstract presented during the ASCO20 Virtual Scientific Program.1  Benoit You, MD, PhD, of Lyon University Hospital,...

Gynecologic Cancers

For Patients With Early-Stage Cervical Cancer, Sentinel Lymph Node Biopsy Declared Oncologically Safe

Bilateral pelvic lymphadenectomy represents the current “gold standard” for lymph node staging in cervical cancer—but an assessment of disease-free and disease-specific survival among patients with early-stage cervical cancer determined that sentinel lymph node biopsy alone is a valid standard of...

Gynecologic Cancers

Can Use of an Algorithm Improve the Accuracy and Efficiency of Cervical Cancer Screening?

In a new study published by Wentzensen et al in the Journal of the National Cancer Institute, a computer algorithm improved the accuracy and efficiency of cervical cancer screening compared with cytology (Papanicolaou [Pap] test), the current standard for follow-up of women who test positive in...

Gynecologic Cancers

Can Use of an Algorithm Improve the Accuracy and Efficiency of Cervical Cancer Screening?

In a new study published by Wentzensen et al in the Journal of the National Cancer Institute, a computer algorithm improved the accuracy and efficiency of cervical cancer screening compared with cytology (Papanicolaou [Pap] test), the current standard for follow-up of women who test positive in...

Gynecologic Cancers

Addition of an ATR Inhibitor to Gemcitabine in Platinum-Resistant High-Grade Serous Ovarian Cancer

As reported in The Lancet Oncology by Panagiotis A. Konstantinopoulos, MD, and colleagues, a phase II trial has shown significantly prolonged progression-free survival with the addition of the ATR (ataxia telangiectasia and Rad3–related) kinase inhibitor berzosertib to gemcitabine in women with...

Gynecologic Cancers

Meta-analysis of Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical Cancer

In a systematic review and meta-analysis of observational studies reported in JAMA Oncology, Nitecki et al found that minimally invasive radical hysterectomy was associated with increased risk of recurrence and all-cause mortality vs open surgery in women with early-stage cervical cancer. Study...

Gynecologic Cancers

Lipophilic Statins May Reduce Mortality in Patients With Ovarian Cancer

Lipophilic statins—a type of medication commonly prescribed to lower blood cholesterol—were associated with reduced mortality in patients with ovarian cancer, according to a study presented by Kala Visvanathan, MD, MHS, and colleagues at the American Association for Cancer Research (AACR) Virtual...

Gynecologic Cancers

ASTRO Issues Clinical Guideline on Radiation Therapy for Cervical Cancer

A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides recommendations for radiation therapy to treat patients with nonmetastatic cervical cancer. The guideline—ASTRO's first for cervical cancer—outlines indications and best practices for external-beam radiation...

Gynecologic Cancers

Breastfeeding: A Public Health Strategy for Reducing Risk of Ovarian Cancer

Although early-stage disease is highly curable, most ovarian cancers are diagnosed at later stages due to a lack of effective screening. As a result, less than 50% of women survive beyond 5 years. Improving prevention by identifying modifiable risk factors could dramatically change the outcome of...

Gynecologic Cancers

Breastfeeding Associated With Reduced Risk of Invasive Ovarian Cancer, Including High-Grade Serous Disease

In a pooled analysis reported in JAMA Oncology,1 Naoko Sasamoto, MD, MPH, of the Obstetrics and Gynecology Epidemiology Center, Brigham and Women’s Hospital, Boston, and colleagues found that breastfeeding, even for durations of 1 to 3 months per birth, was associated with a significant reduction...

Gynecologic Cancers

Expert Point of View: Kathleen N. Moore, MD

Kathleen N. Moore, MD, Associate Professor of Gynecologic Oncology and Director of the Oklahoma TSET Phase I Clinical Trials Program, Stephenson Cancer Center, Oklahoma City, underscored the importance of studying patients with stable disease and less robust partial response, not just those with...

Gynecologic Cancers

Veliparib Plus Chemotherapy Shows Antitumor Activity in Front-Line Treatment of Ovarian Cancer, but Is It Enough?

An updated analysis of the phase III VELIA/GOG-3005 trial, presented during the 2020 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer Webinar Series,1 suggested synergy between the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib and platinum chemotherapy in the...

Gynecologic Cancers

Niraparib for First-Line Maintenance Treatment of Advanced Ovarian Cancer

On April 29, 2020, niraparib was approved for maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.1,2 Supporting Efficacy Data Approval was based on...

Gynecologic Cancers

Expert Point of View: Thomas J. Herzog, MD, and Kathleen N. Moore, MD

Thomas J. Herzog, MD, Deputy Director, University of Cincinnati Cancer Center, who presented a distillation of the PAOLA-1 trial findings along with updated results of the PRIMA trial, called the difference in progression-free survival with the addition of olaparib to bevacizumab “remarkable” after ...

Gynecologic Cancers

Front-Line Maintenance With Olaparib/Bevacizumab Improves Outcomes in Advanced Ovarian Cancer

Proponents of combining bevacizumab with poly (ADP-ribose) polymerase (PARP) inhibition to treat advanced ovarian cancer now have more data to support the maintenance regimen, according to an updated analysis of the phase III PAOLA-1 trial presented during the 2020 Society of Gynecologic Oncology...

Gynecologic Cancers
Immunotherapy

Expert Point of View: TROPHIMMUN Trial

Two gynecologic oncologists and ASCO’s Chief Medical Officer and Executive Vice President Richard L. Schilsky, MD, FACP, FSCT, FASCO, commented on the findings of the TROPHIMMUN trial for The ASCO Post. “The authors demonstrate efficacy of a new treatment approach for gestational trophoblastic...

gynecologic cancers
immunotherapy

Ursula A. Matulonis, MD, on Ovarian Cancer: Roundup of Studies on Olaparib, Cediranib, Mirvetuximab Soravtansine, Bevacizumab, and Pembrolizumab

Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, discusses three important studies focusing on newer therapies for patients with recurrent platinum-sensitive, platinum-agnostic, and advanced recurrent ovarian cancers (Abstracts 6003, 6004, and 6005).

gynecologic cancers

Andres Poveda, MD, on Ovarian Cancer: Assessing Maintenance Olaparib

Andres Poveda, MD, of Initia Oncology, discusses phase III results from the SOLO2 trial, which showed that, compared with placebo, maintenance olaparib improved median overall survival by 12.9 months in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation (Abstract 6002).

Gynecologic Cancers

Olaparib Plus Bevacizumab in Maintenance Treatment for Ovarian, Fallopian Tube, or Primary Peritoneal Cancers

On May 8, 2020, olaparib was granted an expanded indication to include use in combination with bevacizumab for first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line...

gynecologic cancers

Tingyan Shi, MD, PhD, on Ovarian Cancer: Secondary Cytoreductive Surgery for Recurrent Disease

Tingyan Shi, MD, PhD, of Zhongshan Hospital, Fudan University, discusses study results that showed secondary cytoreductive surgery in selected patients extended progression-free survival and might contribute to long-term survival (Abstract 6001).

Breast Cancer
Gynecologic Cancers
Genomics/Genetics

Remote Pre- and Posttest Genetic Counseling for Breast and Ovarian Cancer Risk

Genetic testing for cancer risk can significantly improve the prevention or treatment of hereditary cancers, but studies have shown that people who might have a genetic risk often don't get tested. A collaborative team of researchers have tested a possible solution through a clinical trial aimed at ...

Gynecologic Cancers

Cediranib/Olaparib vs Standard-of-Care Chemotherapy for Platinum-Sensitive Ovarian Cancer

Results of the NRG Oncology phase III clinical trial NRG-GY004 indicated that the addition of the investigational agent cediranib to olaparib and standard platinum-based chemotherapy did not improve progression-free survival outcomes for women with platinum-sensitive ovarian cancer; however,...

gynecologic cancers
covid-19

Merry-Jennifer Markham, MD: Perspectives on Three Abstracts From the ASCO Cancer Communications Chair

Merry-Jennifer Markham, MD, ASCO’s Cancer Communications Chair, gives her views on key papers presented at the ASCO20 Virtual Scientific Program, addressing gynecologic malignancies and COVID-19.

Gynecologic Cancers

Is Sentinel Lymph Node Biopsy Alone Oncologically Safe for Patients With Early-Stage Cervical Cancer?

In a study of patients with early-stage cervical cancer presented by Balaya et al during the Gynecologic Cancer Oral Abstract Session of the ASCO20 Virtual Scientific Program (Abstract 6006), researchers assessed disease-free and disease-specific survival to determine whether sentinel lymph node...

Gynecologic Cancers
Immunotherapy

TROPHIMMUN Trial Finds Avelumab Effective in Rare Gynecologic Tumor Resistant to Chemotherapy

The first trial of immunotherapy for gestational trophoblastic tumors proved effective in almost 50% of patients resistant to single-agent chemotherapy, French investigators reported in an abstract presented during the ASCO20 Virtual Scientific Program.1 The results of the phase II TROPHIMMUN trial ...

Gynecologic Cancers
COVID-19

Gynecologic Oncologist Describes His New Normal in a New York Hospital

During the COVID-19 pandemic, The ASCO Post will be interviewing oncologists on how they and their centers are dealing with the crisis. Here, we speak with Alexander Melamed, MD, MPH, a gynecologic oncologist and Assistant Professor of Obstetrics & Gynecology at NewYork-Presbyterian/Columbia...

Gynecologic Cancers

Expert Point of View: Thomas J. Herzog, MD

Thomas J. Herzog, MD, Deputy Director, University of Cincinnati Cancer Center, who presented a distillation of the PRIMA trial data along with updated results of the phase III PAOLA-1 trial of olaparib plus bevacizumab maintenance, called the data “practice-changing.” “We’ve suspected for a while...

Gynecologic Cancers

Niraparib as First-Line Maintenance Therapy for Advanced Ovarian Cancers

Making sense of maintenance therapy in advanced ovarian cancer has been a tall order since the publication of impressive data for not one but three PARP inhibitors at the European Society for Medical Oncology (ESMO) 2019 Congress.1 The picture became a little clearer on April 29, 2020, however,...

Gynecologic Cancers

Expert Point of View: Shannon N. Westin, MD, MPH, FACOG and Alexander Melamed, MD, MPH

Discussant of the abstract on the WEE1 inhibitor adavosertib, Shannon N. Westin, MD, MPH, FACOG, Associate Professor and clinical investigator at The University of Texas MD Anderson Cancer Center, called the interaction between P53 and WEE1 an “opportunity for synthetic lethality.” She continued:...

Gynecologic Cancers

WEE1 Inhibitor Shows Activity in Recurrent Uterine Serous Carcinoma

Monotherapy with the experimental WEE1 inhibitor adavosertib has shown activity in patients with advanced recurrent or metastatic uterine serous carcinoma,1 according to data presented during the 2020 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer Webinar Series. The initial ...

Gynecologic Cancers

Prevalence of Endosalpingiosis and Association With Ovarian Cancer

Over the last decade, researchers have become concerned about a possible link between a benign gynecologic lesion called endosalpingiosis and ovarian cancer. However, using a diagnostic method typically reserved for specimens suspected of being cancerous, a team has found the prevalence of...

Gynecologic Cancers

Expert Point of View: Don S. Dizon, MD, FACP, FASCO

Commenting on the SOLO2 trial for The ASCO Post was Don S. Dizon, MD, FACP, FASCO, Director of Women’s Cancers at Lifespan Cancer Institute and Professor of Medicine at Brown University, Providence, Rhode Island. “It’s great to get an overall survival advantage from a PARP inhibitor study. Coming...

Gynecologic Cancers

Overall Survival Benefit Shown for Maintenance Olaparib in Ovarian Cancer

For the first time, overall survival has been improved with maintenance therapy involving a poly (ADP-ribose) polymerase (PARP) inhibitor in patients with platinum-sensitive recurrent ovarian cancer associated with BRCA1/2 mutations. In the final, preplanned, overall survival analysis in the...

Gynecologic Cancers

Addition of Olaparib to Bevacizumab Maintenance in Advanced Ovarian Cancer: PAOLA-1 Trial

As reported in The New England Journal of Medicine by Isabelle Ray‑Coquard, MD, PhD, of the Centre Leon Berard, University Claude Bernard Lyon 1 and Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO), Paris, and colleagues, the phase III PAOLA-1 trial has shown a...

Gynecologic Cancers

PARP Inhibitors in Maintenance Treatment for Advanced Ovarian Cancer

Based on multiple phase III prospective trials, there is evidence that both PARP inhibitors and antiangiogenic therapies such as bevacizumab provide benefit when utilized in a maintenance strategy in the first-line treatment of advanced epithelial ovarian cancer (GOG 218, ICON7, SOLO-1, PRIMA,...

Gynecologic Cancers
Immunotherapy

FDA Approves Olaparib Plus Bevacizumab as Maintenance Treatment for Ovarian, Fallopian Tube, or Primary Peritoneal Cancers

On May 8, 2020, the U.S. Food and Drug Administration (FDA) expanded the indication of olaparib (Lynparza) to include its combination with bevacizumab for first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in...

Gynecologic Cancers

Expert Point of View: Alexandra Leary, MD, PhD

Alexandra Leary, MD, PhD, of the Gustave Roussy Institute of Oncology, Paris, underscored the controversy surrounding the use of neoadjuvant chemotherapy in advanced ovarian cancer, suggesting the discord may be “more cultural and emotional than scientific” to some degree. “Some countries, such as ...

Advertisement

Advertisement

Advertisement